CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Status:
Terminated
Trial end date:
2050-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the incidence and pattern of serious
and/or clinically significant infections, malignancies, and other serious adverse event (SAE)
in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective
of this study in this study population is to evaluate disease severity over time in
participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index
(HBI).